Turnstone Biologics Inc

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: -

Employees: -

Market Cap: $17M

Website

Clinical Trials

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Breast Cancer
Colorectal Cancer
Cutaneous Melanoma
Uveal Melanoma
Non-Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma

Interventions: Biological: TBio-4101
Drug: Pembrolizumab

First Posted Date: 2022-10-12

Last Posted Date: 2024-10-07

Lead Sponsor: Turnstone Biologics, Corp.

Target Recruit Count: 60

Registration Number: NCT05576077

Locations: 🇺🇸
University of California Irvine, Irvine, California, United States
🇺🇸
Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸
Allegheny Research Institute, Pittsburgh, Pennsylvania, United States

and more 10 locations

Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors

Phase 1

Terminated

Conditions: Cervical Cancer
Solid Tumor
Microsatellite Stable Colorectal Cancer
Cutaneous Squamous Cell Carcinoma
Mesothelioma
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Renal Cell Carcinoma
Oropharynx Cancer
Melanoma (Skin)

Interventions: Biological: TBio-6517
Biological: Pembrolizumab

First Posted Date: 2020-03-09

Last Posted Date: 2023-11-27

Lead Sponsor: Turnstone Biologics, Corp.

Target Recruit Count: 27

Registration Number: NCT04301011

Locations: 🇺🇸
The Billings Clinic, Billings, Montana, United States
🇰🇷
National Cancer Center, Ilsandong, Korea, Republic of
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 6 locations

MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma

Phase 1

Withdrawn

Conditions: Metastatic Melanoma
Squamous Cell Skin Carcinoma

Interventions: Drug: Ad-MAGEA3
Drug: MG1-MAGEA3
Drug: Pembrolizumab
Drug: Cyclophosphamide

First Posted Date: 2018-12-12

Last Posted Date: 2021-04-06

Lead Sponsor: Turnstone Biologics, Corp.

Registration Number: NCT03773744

This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers

Phase 1

Terminated

Conditions: HPV-Associated Cancers

Interventions: Biological: Ad-E6E7
Biological: MG1-E6E7
Biological: Atezolizumab

First Posted Date: 2018-08-07

Last Posted Date: 2023-04-14

Lead Sponsor: Turnstone Biologics, Corp.

Target Recruit Count: 8

Registration Number: NCT03618953

Locations: 🇺🇸
Billings Clinic, Billings, Montana, United States
🇺🇸
University of Texas-MD Anderson Cancer Center, Houston, Texas, United States
🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada

and more 5 locations

Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: Ad-MAGEA3
Biological: MG1-MAGEA3
Biological: Pembrolizumab

First Posted Date: 2016-08-26

Last Posted Date: 2020-10-06

Lead Sponsor: Turnstone Biologics, Corp.

Target Recruit Count: 16

Registration Number: NCT02879760

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦
Kingston General Hospital, Kingston, Ontario, Canada

and more 3 locations

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy